Key Takeaways
- UltraSight partners with Selvas Healthcare to introduce AI cardiac imaging technology in Korea.
- The joint venture initiates regulatory approval processes for commercialization in Korea and Southeast Asia.
- UltraSight’s software enables real-time guidance for high-quality cardiac ultrasound imaging, enhancing accessibility.
New Partnership to Enhance Cardiac Imaging in Korea
Israel-based UltraSight has formed a partnership with Selvas Healthcare, a subsidiary of Selvas Group based in Korea. This collaboration aims to introduce UltraSight’s cutting-edge cardiac imaging technology, powered by artificial intelligence (AI), to the South Korean market. The joint venture marks the beginning of a process to seek regulatory approvals necessary for the technology’s commercialization and distribution within Korea and the broader Southeast Asian region.
UltraSight’s technology addresses a pressing global issue: the disparity between the increasing number of patients with cardiovascular diseases and the limited access to cardiac ultrasound services. According to UltraSight CEO Davidi Vortman, the company has successfully entered the U.S. market and is now excited to expand its reach into Asia through this partnership with Selvas Healthcare. The long-term vision is to establish a robust presence throughout Asia with their innovative cardiac imaging solutions.
The software developed by UltraSight integrates with point-of-care ultrasound (POCUS) devices. It provides healthcare professionals with real-time guidance, facilitating the acquisition of diagnostic-quality cardiac ultrasound images. This technology is designed to support providers regardless of their experience level, thereby democratizing access to vital cardiac care.
Selvas Healthcare will hold exclusive rights to distribute and commercialize UltraSight’s AI-enhanced cardiac ultrasound technology within Korea, further reinforcing the alignment of their innovative healthcare solutions. This partnership is poised to transform cardiac imaging practices in the region, enabling a more effective response to the growing cardiovascular healthcare needs.
In summary, this new joint venture signifies a crucial step toward improving cardiac healthcare accessibility in Asia, leveraging AI technology to enhance diagnostic capabilities while addressing significant health disparities in the region.
The content above is a summary. For more details, see the source article.
